U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. CDER Rare Diseases Public Workshop: Strategies, Tools and Best Practices for Effective Advocacy in Rare Diseases Drug Development
  1. News & Events for Human Drugs

Public | In Person

Event Title
CDER Rare Diseases Public Workshop: Strategies, Tools and Best Practices for Effective Advocacy in Rare Diseases Drug Development
October 29, 2017

Date:
October 29, 2017

The Food and Drug Administrationʼs (FDA) Center for Drug Evaluation and Research (CDER) is sponsoring a public workshop on rare disease advocacy Monday, October 30, 2017. This public workshop builds upon previous CDER patient advocacy public workshops and is primarily for the rare disease community members to help them effectively understand FDA's needs for enhance drug development. This workshop will include case studies demonstrating the beneficial overlap of effective advocacy techniques and FDA regulations in rare disease drug development.

REGISTRATION

There is no registration fee to attend the public workshop. Early registration is recommended because seating is limited. Registration will be on a first-come, first-served basis. There will be no onsite registration. Persons interested in attending this workshop must register before October 30, 2017 at Eventbrite urldisclaimer icon. Those without internet access should contact Francis Kalush to register.

LOGISTICAL INFORMATION

The workshop will be held at the FDA White Oak Campus, 10903 New Hampshire Avenue Bldg. 31, Room 1503 (Great Room) Silver Spring, Maryland 20993. Public workshop participants (non-FDA employees) should enter through Building 1 of the White Oak Campus where routine security check procedures will be performed. If special accommodations are necessary due to a disability, please contact Francis Kalush at least 7 days in advance.

MEETING MATERIALS

VIDEO RECORDINGS

CONTACT INFORMATION

Francis Kalush Ph.D., Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD  20993, 240-796-5429.

TRANSCIPTS

A transcript of the workshop will be available for review at the FDA Freedom of Information Act and Dockets Public Reading Room in room 1061 of 5630 Fishers Lane, Rockville, MD  20852, and on the Internet at http://www.regulations.gov. Transcripts will also be available in either hard copy or on CD-ROM after submission of a Freedom of Information request

 

Back to Top